Patents by Inventor Anthony R. Means

Anthony R. Means has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CaMKK-? as a target for treating cancer
    Patent number: 9999620
    Abstract: Provided herein are compounds, compositions, including pharmaceutical compositions, having anti-cancer activity. Also provided are methods for diagnosing, detecting, and treating cancer in a subject, as well as a method for evaluating cancer stage in a subject, wherein the methods include determining the amount of a Ca2+/calmodulin dependent kinase kinase (CaMKK) in a sample. Further provided are methods of screening and identifying a compound that inhibits CaMKK.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: June 19, 2018
    Assignee: Duke University
    Inventors: Donald P. McDonnell, Daniel Frigo, Anthony R. Means
  • CAMKK-BETA AS A TARGET FOR TREATING CANCER
    Publication number: 20170027928
    Abstract: Provided herein are compounds, compositions, including pharmaceutical compositions, having anti-cancer activity. Also provided are methods for diagnosing, detecting, and treating cancer in a subject, as well as a method for evaluating cancer stage in a subject, wherein the methods include determining the amount of a Ca2+/calmodulin dependent kinase kinase (CaMKK) in a sample. Further provided are methods of screening and identifying a compound that inhibits CaMKK.
    Type: Application
    Filed: June 17, 2016
    Publication date: February 2, 2017
    Inventors: Donald P. McDonnell, Daniel Frigo, Anthony R. Means
  • CAMKK-BETA AS A TARGET FOR TREATING CANCER
    Publication number: 20130253035
    Abstract: Provided herein are compounds, compositions, including pharmaceutical compositions, having anti-cancer activity. Also provided are methods for diagnosing, detecting, and treating cancer in a subject, as well as a method for evaluating cancer stage in a subject, wherein the methods include determining the amount of a Ca2+/calmodulin dependent kinase kinase (CaMKK) in a sample. Further provided are methods of screening and identifying a compound that inhibits CaMKK.
    Type: Application
    Filed: August 16, 2011
    Publication date: September 26, 2013
    Applicant: Duke University
    Inventors: Donald P. McDonnell, Daniel Frigo, Anthony R. Means
  • CaMKK? as a target for treating obesity
    Patent number: 8207185
    Abstract: A method of treating a condition in a subject in need thereof, comprising administering a calcium/calmodulin dependency kinase kinase (CaMKK) inhibitor in a treatment-effective amount. Conditions which may be treated include obesity (particularly adult obesity), insulin resistance (including high fat diet-induced insulin resistance), hyperglycemia (including hyperglycemia accompanying obesity), diabetes, etc.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: June 26, 2012
    Assignee: Duke University
    Inventor: Anthony R. Means
  • CAMKK(BETA) AS A TARGET FOR TREATING OBESITY
    Publication number: 20100105716
    Abstract: A method of treating a condition in a subject in need thereof, comprising administering a calcium/calmodulin dependency kinase kinase (CaMKK) inhibitor in a treatment-effective amount. Conditions which may be treated include obesity (particularly adult obesity), insulin resistance (including high fat diet-induced insulin resistance), hyperglycemia (including hyperglycemia accompanying obesity), diabetes, etc.
    Type: Application
    Filed: October 4, 2007
    Publication date: April 29, 2010
    Inventor: Anthony R. Means
  • Ca2+/calmodulin-dependent protein kinase IV
    Patent number: 7105312
    Abstract: The present invention relates to Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) and, in particular, to methods of screening compounds for their ability to act as CaMKIV agonists or antagonists. The invention further relates to compounds identified using such methods and to therapeutic methodologies based on same.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: September 12, 2006
    Assignee: Duke University
    Inventor: Anthony R. Means
  • Ca2+/calmodulin-dependent protein kinase IV
    Publication number: 20030059854
    Abstract: The present invention relates to Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) and, in particular, to methods of screening compounds for their ability to act as CaMKIV agonists or antagonists. The invention further relates to compounds identified using such methods and to therapeutic methodologies based on same.
    Type: Application
    Filed: April 11, 2002
    Publication date: March 27, 2003
    Inventor: Anthony R. Means
  • Immunosuppression
    Publication number: 20030027224
    Abstract: The present invention relates, in general, to immunosuppression and, in particular, to a method of inducing an immunosuppressive effect. The invention further relates to a method of screening compounds for immunosuppressive activity.
    Type: Application
    Filed: July 12, 2002
    Publication date: February 6, 2003
    Applicant: DUKE UNIVERSITY
    Inventor: Anthony R. Means
  • Method for screening a test compound for potential as an immunosuppressive drug candidate
    Patent number: 6436656
    Abstract: The present invention relates, in general, to immunosuppression and, in particular, to a method of inducing an immunosuppressive effect. The invention further relates to a method of screening compounds for immunosuppressive activity.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: August 20, 2002
    Assignee: Duke University
    Inventor: Anthony R. Means
  • 17.beta.-hydroxy-17.alpha.-methyl-5.alpha.-androstano[3,2-c]pyrazole 17-methyl ether
    Patent number: 4585765
    Abstract: 17.beta.-Hydroxy-17.alpha.-methyl-5.alpha.-androstano[3,2-c]pyrazole 17-methyl ether is a very potent reversible male contraceptive which has a very low degree of androgenic side effects. Upon cessation of administration fertility promptly returns.
    Type: Grant
    Filed: April 16, 1980
    Date of Patent: April 29, 1986
    Assignee: The Upjohn Company
    Inventors: Donald J. Tindall, Anthony R. Means
  • 17.beta.-Hydroxy-17.alpha.-methyl-5.alpha.-androstano-[3,2-c]pyrazole 17-methyl ether
    Patent number: 4356175
    Abstract: 17.beta.-Hydroxy-17.alpha.-methyl-5.alpha.-androstano[3,2-c]pyrazole 17-methyl ether is a very potent reversible male contraceptive which has a very low degree of androgenic side effects. Upon cessation of administration fertility promptly returns.
    Type: Grant
    Filed: October 10, 1978
    Date of Patent: October 26, 1982
    Assignee: The Upjohn Company
    Inventors: Donald J. Tindall, Anthony R. Means